What is Sterilucent?
Founded in 2004, Sterilucent operates at the intersection of advanced engineering and life sciences. The company is best known for its MOXIsmart Life Science Processing System, which leverages patented iQVHP technology to deliver superior sterilization outcomes. By focusing on minimizing material degradation while maximizing decontamination efficacy, Sterilucent addresses critical pain points for industrial clients. The firm's historical development has been bolstered by strategic support from the National Institute of Health and the Department of Defense, validating its technical rigor and utility in high-stakes environments. Its market position is defined by a commitment to operational efficiency and cost-effective, reliable sterilization solutions for complex medical and scientific applications.
How much funding has Sterilucent raised?
Sterilucent has raised a total of $4.3M across 4 funding rounds:
Private Equity
$3.4M
Private Equity
$564K
Debt
$150K
Debt
$228K
Private Equity (2012): $3.4M, investors not publicly disclosed
Private Equity (2014): $564K, investors not publicly disclosed
Debt (2020): $150K supported by PPP
Debt (2021): $228K featuring PPP
Key Investors in Sterilucent
PPP
Public-Private Partnership
Undisclosed Private Equity
A private equity firm focused on long-term capital appreciation through strategic investments in industrial technology and life science infrastructure.
Undisclosed Investor
An institutional backer participating in the funding round to support the advancement of proprietary decontamination systems.
What's next for Sterilucent?
With the recent influx of capital, Sterilucent is well-positioned to accelerate its enterprise-level expansion. The company is expected to prioritize the commercial scaling of its iQVHP technology, targeting broader adoption within the medical device manufacturing sector. Strategic initiatives will likely focus on enhancing supply chain resilience and deepening market penetration in regions with stringent regulatory requirements for decontamination. As the firm transitions into this next phase of growth, the focus remains on maintaining its technological edge while optimizing the MOXIsmart platform for diverse industrial use cases, ensuring that Sterilucent remains a leader in the evolving landscape of life science processing infrastructure.
See full Sterilucent company page
